Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

Salem, Mohamed EYin, JunWeinberg, Benjamin ARenfro, Lindsay APederson, Levi DMaughan, Timothy SAdams, Richard AVan Cutsem, EricFalcone, AlfredoTebbutt, Niall CSeymour, Matthew TDiaz-Rubio, EduardoAranda, EnriqueBokemeyer, CarstenHeinemann, VolkerWasan, Harpreetde Gramont, AimeryGrothey, AxelShi, QianSargent, Daniel JMarshall, John L2023-01-252023-01-252018-08-22Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, et al. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. Eur J Cancer. 2018 Nov;103:205-213http://hdl.handle.net/10668/13010Patients with left-sided colon tumours have better survival and respond differently to biologics compared with patients with right-sided tumours. Left-sided colon tumours and rectal cancers are often grouped together. Herein, we examined the clinicopathological differences and outcomes between left-sided colon and rectal cancers. Data from 2879 metastatic colorectal cancer patients enrolled on six first-line clinical trials during 2004-2010 were pooled. Patients were included if the primary tumour origin was clearly defined. Progression-free survival (PFS) and overall survival (OS) were compared in the two groups after adjusting for patient and tumour characteristics, metastatic sites and the first-line regimen. In total, 1374 patients with metastatic left-sided colon cancer and 1505 patients with metastatic rectal cancers were evaluated. Left-sided colon cancer patients were more likely to be female (40.1% versus 32.6%; P The site of tumour origin within the left side was not prognostic of outcomes. Moreover, neither bevacizumab nor cetuximab impacted, differently, the findings of the comparisons in outcomes between patients with left-sided colon tumours or rectal cancers.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/BevacizumabCetuximabLeft-sided colon cancerOutcomesRectal cancerColonic neoplasmsFemaleGene poolHumansMaleMiddle agedRectal neoplasmsClinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.Research article30268921open accessFemeninoMasculinoNeoplasias del colonNeoplasias del rectoPersona de mediana edadPool de genes10.1016/j.ejca.2018.08.0201879-0852http://eprints.whiterose.ac.uk/139176/7/2018%20EJC%20%20ARCAD%20%20pooled%20analysis.pdf